A PYMNTS Company

FTC Reaches Preliminary Settlement With US Anesthesia Partners Over Texas Market Competition

By  |  April 23, 2026
FTC Reaches Preliminary Settlement With US Anesthesia Partners Over Texas Market Competition

The Federal Trade Commission (FTC) has announced an agreement in principle with U.S. Anesthesia Partners Inc. (USAP) to resolve ongoing litigation tied to alleged anticompetitive practices in Texas. The case, originally filed in 2023, accused the company of violating federal antitrust laws through a long-running effort to dominate the state’s anesthesia services market.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    Subscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    According to a statement, the FTC alleged that USAP engaged in a decade-long strategy of acquiring nearly every large anesthesia practice across Texas. Regulators described the approach as a “roll-up scheme” designed to consolidate providers under one umbrella, ultimately creating a dominant entity with the leverage to raise prices.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    The agency’s complaint further claimed that USAP’s actions resulted in significantly higher costs for patients. Per a statement, the FTC said the company’s “multi-pronged anticompetitive strategy and resulting dominance cost Texans tens of millions of dollars more each year for anesthesia services than before USAP was created.”

    While the agreement marks a step toward resolving the dispute, key details remain undisclosed. According to a statement, the substance of the settlement is currently confidential to allow USAP time to complete negotiations and implement the required changes. The FTC indicated that, if fully executed, the settlement would restore competitive conditions in the Texas anesthesia market and align with the agency’s established settlement practices.

    However, regulators made clear that the agreement is not yet final. Per a statement, the FTC warned that if USAP does not fully comply with the settlement terms, the agency will return to district court to continue litigation over the alleged unlawful acquisitions.

    The Commission voted 2-0 to authorize staff to move forward with the preliminary agreement. In the meantime, the FTC’s Health Care Division has been cleared to seek a stay of proceedings while USAP works to implement relief measures for consumers in Texas.

    Any joint motions related to the case will require approval from the district court. Additionally, a final order resolving the litigation would need both a formal Commission vote and court approval before taking effect.

    Source: FTC